

Press release for immediate release

Genomtec® receives notice of allowance on the granting of its patent by the Japan Patent Office

Wroclaw, Poland - September 21, 2021. - Genomtec S.A. "GMT", a NewConnect listed medical technology company, has received a notice of allowance from the Japan Patent Office (JPO) granting the Company patent protection for the Genomtec®ID device and the technology invented by Genomtec SA.

The invention with the new patent protection covers the key technical solutions related to the proprietary contactless heating and temperature detection system developed for POCT platforms, including Genomtec® ID.

This is the first patent granted by JPO and the fourth significant intellectual property secured by Genomtec. The company has currently pending more than twenty patent applications worldwide.

"Each additional area of patent protection we receive protects us from the copying of our technology and thus increases Genomtec's value in the global market of companies specializing in molecular diagnostics. It also strengthens the competitiveness of our key project - which is Genomtec ID". - said Miron Tokarski, co-founder and CEO of Genomtec SA. "Both United States and now Japan, where the core technology behind Genomtec®ID are already under patent protection, are some of the most dynamic countries where similar inventions are made. This puts us in a strong negotiating position before signing commercial agreements with selected partners to execute our commercialization strategy." - He adds.

The patent proceedings are aimed at securing key interests and are part of Genomtec's growth strategy which includes pursuing innovation in clinical diagnostics and building its IP portfolio.

#####

Additional information available at:

Genomtec S.A.
Magdalena Kicińska
+48 604 201 230
m.kicinska@genomtec.com

About Genomtec S.A.

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.



The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wrocław.

More information at: www.genomtec.com